Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR5 | P35346 | 3/20 | 0.58 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | MCHR1 | Q99705 | 6/20 | 0.53 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1790544 | 0.89 | SSTR5 (0.57) | SSTR5MEN1KMT2AMCHR1KDM4E | |
| SCHEMBL1786965 | 0.89 | MCHR1 (0.52) | SSTR5MCHR1USP2POLB | |
| SCHEMBL1787892 | 0.88 | SSTR5 (0.55) | SSTR5MCHR1POLB | |
| SCHEMBL1787380 | 0.88 | SSTR5 (0.55) | SSTR5MEN1KMT2AMCHR1 | |
| SCHEMBL1788399 | 0.88 | MCHR1 (0.58) | SSTR5KMT2AMCHR1HDAC8HDAC6 | |
| SCHEMBL1786527 | 0.86 | SSTR5 (0.54) | SSTR5MCHR1POLB | |
| Formic Acid SCHEMBL1785841 | 0.85 | SSTR5 (0.52) | SSTR5MCHR1POLB | |
| SCHEMBL1787246 | 0.83 | MCHR1 (0.54) | SSTR5KMT2AMCHR1KDM4EALDH1A1 | |
| SCHEMBL1786360 | 0.83 | SSTR5 (0.53) | SSTR5MCHR1ALDH1A1POLB | |
| SCHEMBL1787608 | 0.81 | SSTR5 (0.58) | SSTR5MCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110124674-A1 | 5/5-OR 5/6-MEMBERED CONDENSED RING CYCLOALKYLAMINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2011-05-26 | — | — | US | disclosed |
| US-20110124674-A1 | 5/5-OR 5/6-MEMBERED CONDENSED RING CYCLOALKYLAMINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2011-05-26 | — | — | US | disclosed |
| WO-2010013595-A1 | (5-MEMBERED)-(5-MEMBERED) OR (5-MEMBERED)-(6-MEMBERED) FUSED RING CYCLOALKYLAMINE DERIVATIVE | 萬有製薬株式会社 (JP) | 2010-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124674-A1 | 5/5-OR 5/6-MEMBERED CONDENSED RING CYCLOALKYLAMINE DERIVATIVE | MCHR1, MC5R, MCHR2 | SSTR5 22/4885HTR4 94/4885MEN1 304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.